Rocket: Chardan Capital maintains a 'Buy' Rating, The Target Price is $12

Chardan Capital maintains 'Buy' rating on Rocket(RCKT).

The target price is $12, compare with $17 previously.

[Recent Rating]

Date	Agency	Change	Rating	Rating （previously）	Target Price	Target Price（previously）
2025-07-25	B of A Securities	Downgrades	Neutral	Buy	$4	$9
2025-07-24	Needham	Maintains	Hold	Hold	$--	$--
2025-07-24	Chardan Capital	Maintains	Buy	Buy	$12	$17

[Recent Earning Results] Rocket posted the Q1 of its 2025 financial results on 5/8/2025, reporting net income of USD -61.33 million in the first quarter, narrowing 1.16% from USD -62.05 million year over year.

[Company Profile] Rocket Pharmaceuticals, Inc. was incorporated under the laws of the State of Delaware on July 7, 1999. The company is a fully integrated, late-stage biotechnology company focused on the development of first, only and best in class gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases.